About Infectious Disease Treatment
Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. Anti-infective drugs can act via host defence system or can directly target the causative agent.
TechNavio's analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Infectious Disease Treatment market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include:
• Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials)
• Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals)
• Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs)
• Antiparasitic drugs
TechNavio's report, the Global Infectious Disease Treatment Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Infectious Disease Treatment market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Pfizer
Other Prominent Vendors
• Achillion Pharmaceuticals
• AbbVie
• Astellas Pharma
• AstraZeneca
• Auritec Pharmaceuticals
• Bayer
• Bristol-Myers Squibb
• Chimerix Pharmaceuticals
• Cubist
• Eli Lilly
• Isis Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis
• pSivida
• Sanofi
Market Driver
• Launch of Direct Acting Antivirals
• For a full, detailed list, view our report
Market Challenge
• Generic Erosion
• For a full, detailed list, view our report
Market Trend
• Emergence of IFN-free Therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Application
08. Global Antibacterial Drugs Market
08.1 Introduction
08.2 Market Size and Forecast
08.3 Market Segmentation by Chemical Class
08.4 Market Segmentation by Drug Origin
09. Global Antifungal Drugs Market
09.1 Introduction
09.2 Market Size and Forecast
09.3 Market Segmentation by Chemical Class
09.4 Market Segmentation by Geography
09.4.1 Antifungal Drugs Market in the US
09.4.2 Antifungal Drugs Market in Europe
10. Global Antiviral Drugs Market
10.1 Introduction
10.2 Market Size and Forecast
10.3 Market Segmentation by Disease
10.4 Global Hepatitis C Drugs Market
10.4.1 Market Size and Forecast
10.4.2 Geographical Segmentation
10.5 Global Hepatitis B Drugs Market
10.5.1 Market Size and Forecast
10.6 Global HIV Drugs Market
10.6.1 Market Size and Forecast
11. Global Antiparasitic Drugs Market
11.1 Market Size and Forecast
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 Gilead Sciences
20.2.2 GlaxoSmithKline
20.2.3 Pfizer
20.2.4 F. Hoffmann-La Roche
20.2.5 Johnson & Johnson
20.2.6 Merck
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 F. Hoffmann La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Geographical Segmentation by Revenue 2013
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Gilead Sciences
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Geographical Segmentation by Revenue 2013
21.2.4 Recent Developments
21.2.5 SWOT Analysis
21.3 GlaxoSmithKline plc
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Johnson & Johnson
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation by Revenue 2013
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Geographical Segmentation by Revenue 2013
21.4.6 Business Strategy
21.4.7 Recent Developments
21.4.8 SWOT Analysis
21.5 Merck
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Sales by Geography
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Infectious Disease Treatment Market 2013-2018 (US$ million)
Exhibit 3: Global Infectious Disease Treatment Market Segmentation by Application
Exhibit 4: Global Infectious Disease Treatment Market Segmentation by Application 2013
Exhibit 5: Global Infectious Disease Treatment Market Segmentation by Application 2018
Exhibit 6: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018 (US$ million)
Exhibit 7: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018
Exhibit 8: Snapshot of Global Infectious Disease Treatment Market Segments 2013-2018
Exhibit 9: YoY Growth Rate of Global Infectious Disease Treatment Market Segments 2013-2018
Exhibit 10: Global Antibacterial Drugs Market: Key Drivers and Challenges
Exhibit 11: Global Antibacterial Drugs Market 2013-2018 (US$ million)
Exhibit 12: Global Antibacterial Drugs Market Segmentation by Chemical Class
Exhibit 13: Cephalosporin Segmentation by Generation of Drugs
Exhibit 14: Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
Exhibit 15: Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
Exhibit 16: Global Antibacterial Drugs Market Segmentation by Drug Origin
Exhibit 17: Global Antifungal Drugs Market: Key Drivers and Challenges
Exhibit 18: Global Antifungal Drugs Market 2013-2018 (US$ million)
Exhibit 19: Global Antifungal Drugs Market Segmentation by Chemical Class
Exhibit 20: Global Antifungal Drugs Market Segmentation by Chemical Class 2013
Exhibit 21: Global Antifungal Drugs Market by Geography Segmentation 2013
Exhibit 22: Antifungal Drugs Market in the US 2013-2018 (US$ million)
Exhibit 23: Antifungal Drugs Market in Europe 2013-2018 (US$ million)
Exhibit 24: Global Antiviral Drugs Market: Key Drivers and Challenges
Exhibit 25: Global Antiviral Drugs Market 2013-2018 (US$ million)
Exhibit 26: Global Antiviral Drugs Market Segmentation by Disease
Exhibit 27: Global Antiviral Drugs Market Segmentation by Disease 2013
Exhibit 28: Global Antiviral Drugs Market Segmentation by Disease 2018
Exhibit 29: Global Hepatitis C Drugs Market 2013-2018 (US$ million)
Exhibit 30: Global Hepatitis C Market by Geographical Segmentation 2013
Exhibit 31: Global Hepatitis B Drugs Market 2013-2018 (US$ million)
Exhibit 32: Global HIV Drugs Market 2013-2018 (US$ million)
Exhibit 33: Global Antiparasitic Drugs Market: Key Drivers and Challenges
Exhibit 34: Global Antiparasitic Drugs Market 2013-2018 (US$ million)
Exhibit 35: Global Infectious Disease Treatment Market by Geographical Segmentation 2013
Exhibit 36: Global Infectious Disease Treatment Market Share Analysis 2013
Exhibit 37: Revenue of Stribild 2012-2013 (US$ million)
Exhibit 38: Revenue of Truvada 2011-2013 (US$ million)
Exhibit 39: Revenue of Emtriva 2011-2013 (US$ million)
Exhibit 40: Revenue of Atripla 2011-2013 (US$ million)
Exhibit 41: Revenue of Complera/Eviplera 2011-2013 (US$ million)
Exhibit 42: Revenue of Viread 2011-2013 (US$ million)
Exhibit 43: Revenue of Hepsera 2011-2013 (US$ million)
Exhibit 44: Revenue of AmBisome 2011-2013 (US$ million)
Exhibit 45: Gilead Sciences: Percentage Share of Key Antiviral Drugs 2013
Exhibit 46: Share of Key Antiviral Drugs in Gilead Sciences' Revenue 2013
Exhibit 47: Gilead Sciences: Percentage Share of Key Anti-infective Drugs 2011-2013
Exhibit 48: Gilead Sciences: Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
Exhibit 49: Gilead Sciences: Revenue Trend of Key Anti-infective Drugs 2011-2013
Exhibit 50: Gilead Sciences' Key Anti-infective Drugs 2011-2013
Exhibit 51: Share of GlaxoSmithKline's Anti-infective Segment 2013
Exhibit 52: GlaxoSmithKline's Key Antiviral Drugs Portfolio
Exhibit 53: Share of Key Antiviral Drugs in GlaxoSmithKline's Antiviral Drugs Segment 2013
Exhibit 54: Geography-wise Segmentation of GlaxoSmithKline's Antiviral Drugs Segment 2013
Exhibit 55: Geography-wise Segmentation of GlaxoSmithKline's Key Anti-viral Drugs 2013
Exhibit 56: Geography-wise Segmentation of GlaxoSmithKline's Key Anti-viral Drugs 2013 (US$ million)
Exhibit 57: GlaxoSmithKline's Key Antibacterial Drugs Portfolio
Exhibit 58: Share of Augmentin in GlaxoSmithKline's Antibacterial Drugs Segment Revenue 2013
Exhibit 59: Region-wise Segmentation of GlaxoSmithKline's Antibacterial Drugs 2013 (US$ million)
Exhibit 60: Geography-wise Segmentation of GlaxoSmithKline's Antibacterial Drugs 2013
Exhibit 61: Geography-wise Segmentation of GlaxoSmithKline's Antibacterial Drugs Segment 2013
Exhibit 62: GlaxoSmithKline's Key Anti HIV Drugs Portfolio (ViiV Healthcare)
Exhibit 63: Geography-wise Segmentation of GlaxoSmithKline's Key Anti HIV Drugs 2013
Exhibit 64: Geography-wise Segmentation of GlaxoSmithKline's Key Anti HIV Drugs 2013 (US$ million)
Exhibit 65: Geography-wise Segmentation GlaxoSmithKline's Anti HIV Drugs Segment 2013
Exhibit 66: Pfizer's Key Anti-infective Drugs Portfolio
Exhibit 67: Pfizer's Key Anti-infective Drug Sales 2011-2013
Exhibit 68: Share of F. Hoffmann-La Roche's Key Anti-infective Drugs 2013
Exhibit 69: Geography-wise Segmentation of Pegasys 2013
Exhibit 70: Geography-wise Segmentation of Tamiflu 2013
Exhibit 71: Share of Johnson & Johnson's Key Anti-infective Drugs 2013
Exhibit 72: Share of Johnson & Johnson's Anti-infective Drugs 2011-2013
Exhibit 73: Johnson & Johnson's Anti-infective Drugs Sales 2011-2013 (US$ million)
Exhibit 74: Johnson & Johnson: Drug-wise Sales Comparison of Anti-infective Drugs 2011-2013
Exhibit 75: Merck's Key Anti-infective Drugs Portfolio
Exhibit 76: Share of Merck's Key Anti-infective Drugs 2013
Exhibit 77: Share of Merck's Key Anti-infective Drugs 2011-2013
Exhibit 78: Share of Merck's Key Anti-infective Drugs 2011-2013 (US$ million)
Exhibit 79: Merck's Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
Exhibit 80: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 81: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 82: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 83: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 84: Gilead Sciences: Geographical Segmentation by Revenue 2013
Exhibit 85: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 86: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 87: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 88: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 89: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 90: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 91: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 92: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 93: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 94: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 95: Pfizer Inc.: Business Segmentation
Exhibit 96: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 97: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 98: Pfizer Inc.: Revenue by Geography 2013
